INGN-201: Introgen Therapeutics

Current Opinion in Investigational Drugs

Volumn 2, Issue 12, 2001, Pages 1776-1785

  Brukner, Ivan ^a  

^a Galileo Genomics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AD5 ANTIBODY; ADVEXIN; ANTIBODY; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CISPLATIN; DOXORUBICIN; E2F 1; GENE PRODUCT; PACLITAXEL; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; HEAD AND NECK CANCER; HUMAN; IMMUNE COMPLEX DISEASE; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PHARMACODYNAMICS; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; GENE THERAPY; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035686546     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Introgen Therapeutics and Rhône-Poulenc Rorer to collaborate on gene therapy programs for cancer
2. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
3. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
4. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas
5. Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro
6. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer
7. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
8. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck
9. Safety evaluation of Ad5CMV-p53 in vitro and in vivo
10. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma
11. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus
12. Introgen Therapeutics: A challenge for cancer
13. Results of first gene therapy study of demonstrate tumor regression and positive safety profile in head and neck cancer
14. New cancer strategies: p53 diagnostics & Therapeutics, Cambridge Healthtech's Second Annual Conference, Washington DC, USA
15. Gene Therapy and Molecular Biology International Conference (Part II), Agia Pelagia, Crete, Greece
16. Company profile
17. Introgen/RPR broaden p53 gene therapy trials
18. Introgen Therapeutics Company profile
19. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers
20. The route of administration is a major determinant of the transduction efficacy of rat tissues by adenoviral recombinants
21. The University of Texas System awarded patent for use of p53 tumor suppressor gene in combination with DNA damaging agents. Introgen Therapeutics Inc owns exclusive, worldwide license
22. Researchers at the University of Texas MD Anderson Cancer Center report on completed phase I adenoviral-p53 gene therapy trial for patients with non-small cell lung cancer therapy demonstrates positive safety profile, alone and in combination with Cisplatin
23. Clinical gene therapy strategies phase I/II results with adenoviral p53 (INGN 201) gene transfer in advanced head and neck and non small cell lung cancers
24. Introgen Therapeutics, Rhône-Poulenc Rorer and National Cancer Institute sign cooperative research and development agreement - Results of adenoviral-p53 gene therapy trials highlighted at ASCO conference
25. Gene therapy data show non-toxic control of tumor growth in advanced head and neck cancer p53 therapy increases survival of cancer patients up to 8 months
26. American Society of Clinical Oncology - 35th Annual Meeting (Part VII), Atlanta, GA, USA
27. Introgen Therapeutics achieves $6 million phase III milestone payment from Rhône-Poulenc Rorer
28. Cancer Gene Therapy - First International Conference, London, UK
29. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer
30. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
31. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene
32. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
33. Biological Therapy of Cancer - Fifth Symposium (Part II), Munich, Germany
34. National Institutes of Health recombinant DNA Advisory Committee completes review of phase III clinical trial for cancer gene therapy
35. Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells
36. Antitumor effect of adenovirus-mediated bax gene transfer on p53-sensitive and p53-resistant cancer lines
37. Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells
38. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: Potential application of gene therapy to endometrial cancer
39. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
40. Adenovirus-mediated p53 gene therapy for human gliomas
41. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement
42. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status
43. Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines
44. Differential regulation of p53-dependent and -independent proliferating cell nuclear antigen gene transcription by 12 S E1A oncoprotein requires CBP
45. Viral and non-viral vectors for cancer gene therapy
46. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck
47. Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer
48. Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck
49. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis
50. A simple and sensitive method for detecting adenovirus in serum and urine
51. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53
52. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism
53. Drug development pipeline: INGN-201
54. The University of Texas System awarded patent for use of p53 gene in combination with DNA-damaging agents utilizing any type of delivery system - Introgen Therapeutics Inc owns exclusive worldwide license
55. Aventis Pharma - Pipeline: Aventis Pharma key filings and approvals 2000
56. Introgen's p53 drug awarded patent - Introgen Therapeutics owns exclusive, worldwide licence from the University of Texas System
57. Introgen reports results for the second quarter of fiscal 2001
58. Introgen receives patent for commercial production of adenovirus
59. Aventis Pharma to create a new Gencell Entity; Aventis Pharma and Introgen to restructure their collaboration in gene therapy
60. American Society of Clinical Oncology - 37th Annual Meeting (Part V) - Overnight Report, San Francisco, CA, USA
61. Introgen announces second phase III gene therapy trial for cancer; Enrollment continuing under Introgen management
62. Introgen adenovirus demonstrates safety in hundreds of patients; Biosafety data presented in 190 patients at Annual ASCO Meeting
63. Introgen's intravenously administered gene therapy demonstrates safety and establishes basis for systemic treatment for metastatic cancer
64. Introgen reports significant increase in responses to combination therapy for phase II lung cancer study; Phase I results for ovarian cancer also presented at annual ASCO meeting
65. American Society of Clinical Oncology - 37th Annual Meeting (Part VII), San Francisco, CA, USA
66. Induction of pro-apoptotic mediates and tumor regression following intratumoral delivery of adenoviral p53 (RPR/INGN 201) and radiation therapy in patients with non-small lung cell cancer (NSCLC)
67. Phase I intraperitoneal adenoviral p53 gene transfer in ovarian cancer
68. Clinical biosafety, distribution, genetic stability and potential for transmission of adenoviral vectors for gene transfer (therapy): Data from 190 subjects treated intra-tumorally with RPR/INGN 201 (Ad5CMV-p53)
69. A phase I and pharmacokinetic study of intravenous (iv) p53 gene therapy with RPR/INGN-201 in patients (pts) with advanced cancer
70. Gene therapy in bladder cancer: Phase I results with Ad5CMV-p53 (INGN-201)
71. Introgen Therapeutics receives $25 million from Aventis Pharma
72. Drug development pipeline: INGN-201, INGN-111 and INGN-212